This forms part of a total investment of EUR 500 million co-financed by EUROfusion, the EU programme to produce safe, clean nuclear fusion energy by 2050. The transaction is enabled by a guarantee from the EU budget, under the Investment Plan for Europe - the Juncker Plan - and its European Fund for Strategic Investments (EFSI). Meanwhile, in France the European Investment Fund (EIF) is investing EUR 40 million in the SME compartment of SP EuroCréances 2018, a private debt fund focusing on Senior Secured Debt to French SMEs and managed by the private debt team at Schelcher Prince Gestion. This is one of the first investments, and the second one in France, made by the EIF under the “Private Credit Tailored for SMEs” programme. The EIB also announced an investment of EUR 80 million in the Eiffel Essentiel Fund. The fund supports companies whose purpose is to meet the most basic human needs of food, health and preservation of the environment. In Germany, the EIF, the Austria Wirtschaftsservice GmbH (Vienna, Austria), and the Max Planck Foundation (Munich, Germany) have committed a total of EUR 60 million in funding for KHAN-I to support early-stage drug discovery projects. The EIF will provide up to EUR 30 million through “InnovFin Equity Facility for Early Stage” (IFE), an integral part of the European growth initiative.